UBS Group
EIDX

UBS Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

UBS Group’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-171
Closed -$23K – 9917
2020
Q4 		$23K Buy
171
+155
+969% +$13.7K ﹤0.01% 6859
2020
Q3 		$1K Sell
16
-316
-95% -$14.2K ﹤0.01% 7907
2020
Q2 		$16K Sell
332
-2,929
-90% -$136K ﹤0.01% 6716
2020
Q1 		$160K Sell
3,261
-8,381
-72% -$427K ﹤0.01% 4897
2019
Q4 		$668K Buy
11,642
+10,781
+1,252% +$534K ﹤0.01% 4573
2019
Q3 		$31K Sell
861
-475
-36% -$18.6K ﹤0.01% 6480
2019
Q2 		$41K Buy
1,336
+1,174
+725% +$31.8K ﹤0.01% 6094
2019
Q1 		$4K Sell
162
-573
-78% -$9.2K ﹤0.01% 7294
2018
Q4 		$10K Sell
735
-972
-57% -$12.3K ﹤0.01% 7257
2018
Q3 		$17K Buy
1,707
+121
+8% +$1.99K ﹤0.01% 6903
2018
Q2 		$32K Buy
+1,586
New +$33.3K ﹤0.01% 6346

UBS Group's EIDX Position: Q1 2021 in Review

UBS Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 171 shares — an estimated $23K sold.

UBS Group first reported a position in EIDX in Q2 2018 and held it in 11 quarters. The position peaked at $668K in Q4 2019. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • UBS Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • UBS Group sold 171 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $23K.
  • UBS Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 11 quarters.
  • UBS Group's Eidos Therapeutics, Inc. Common Stock position peaked at $668K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on UBS Group's 13F filing for Q1 2021, filed 12 May 2021.